|
1
|
Printz C: American Cancer Society reports
progress in reducing cancer deaths: However, some groups still lag
behind this trend. Cancer. 117:4573–4574. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lash TL, Fox MP and Silliman RA: Reduced
mortality rate associated with annual mammograms after breast
cancer therapy. Breast J. 12:2–6. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Montemurro F, Del Mastro L, De Laurentiis
M and Puglisi F: Endocrine therapy in premenopausal women with
breast cancer: A critical appraisal of current evidence. Expert Rev
Anticancer Ther. 16:211–218. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fisher B, Costantino JP, Wickerham DL,
Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N,
Atkins J, et al: Tamoxifen for prevention of breast cancer: Report
of the National Surgical Adjuvant Breast and Bowel Project P-1
Study. J Natl Cancer Inst. 90:1371–1388. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jordan VC: Tamoxifen: A most unlikely
pioneering medicine. Nat Rev Drug Discov. 2:205–213. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ring A and Dowsett M: Mechanisms of
tamoxifen resistance. Endocr Relat Cancer. 11:643–658. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jaiyesimi IA, Buzdar AU, Decker DA and
Hortobagyi GN: Use of tamoxifen for breast cancer: Twenty-eight
years later. J Clin Oncol. 13:513–529. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Glaros S, Atanaskova N, Zhao C, Skafar DF
and Reddy KB: Activation function-1 domain of estrogen receptor
regulates the agonistic and antagonistic actions of tamoxifen. Mol
Endocrinol. 20:996–1008. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li Z, Carrier L and Rowan BG:
Methylseleninic acid synergizes with tamoxifen to induce
caspase-mediated apoptosis in breast cancer cells. Mol Cancer Ther.
7:3056–3063. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Li Z, Wang N, Fang J, Huang J, Tian F, Li
C and Xie F: Role of PKC-ERK signaling in tamoxifen-induced
apoptosis and tamoxifen resistance in human breast cancer cells.
Oncol Rep. 27:1879–1886. 2012.PubMed/NCBI
|
|
12
|
Cavalli LR and Liang BC: Mutagenesis,
tumorigenicity, and apoptosis: Are the mitochondria involved? Mutat
Res. 398:19–26. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Simon HU, Haj-Yehia A and Levi-Schaffer F:
Role of reactive oxygen species (ROS) in apoptosis induction.
Apoptosis. 5:415–418. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Storz P: Reactive oxygen species in tumor
progression. Front Biosci. 10:1881–1896. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Katzenellenbogen BS, Fang H, Ince BA,
Pakdel F, Reese JC, Wooge CH and Wrenn CK: William L. McGuire
Memorial Symposium. Estrogen receptors: Ligand discrimination and
antiestrogen action. Breast Cancer Res Treat. 27:17–26. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Katzenellenbogen BS, Montano MM, Le Goff
P, Schodin DJ, Kraus WL, Bhardwaj B and Fujimoto N: Antiestrogens:
Mechanisms and actions in target cells. J Steroid Biochem Mol Biol.
53:387–393. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Amin S, Kumar A, Nilchi L, Wright K and
Kozlowski M: Breast cancer cells proliferation is regulated by
tyrosine phosphatase SHP1 through c-jun N-terminal kinase and
cooperative induction of RFX-1 and AP-4 transcription factors. Mol
Cancer Res. 9:1112–1125. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Mandlekar S and Kong AN: Mechanisms of
tamoxifen-induced apoptosis. Apoptosis. 6:469–477. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mamay CL, Mingo-Sion AM, Wolf DM, Molina
MD and Van Den Berg CL: An inhibitory function for JNK in the
regulation of IGF-I signaling in breast cancer. Oncogene.
22:602–614. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Montano MM and Katzenellenbogen BS: The
quinone reductase gene: A unique estrogen receptor-regulated gene
that is activated by antiestrogens. Proc Natl Acad Sci USA.
94:2581–2586. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nazarewicz RR, Zenebe WJ, Parihar A,
Larson SK, Alidema E, Choi J and Ghafourifar P: Tamoxifen induces
oxidative stress and mitochondrial apoptosis via stimulating
mitochondrial nitric oxide synthase. Cancer Res. 67:1282–1290.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Umekita Y, Ohi Y, Sagara Y and Yoshida H:
Overexpression of cyclinD1 predicts for poor prognosis in estrogen
receptor-negative breast cancer patients. Int J Cancer. 98:415–418.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Altucci L, Addeo R, Cicatiello L, Dauvois
S, Parker MG, Truss M, Beato M, Sica V, Bresciani F and Weisz A:
17beta-Estradiol induces cyclin D1 gene transcription,
p36D1-p34cdk4 complex activation and p105Rb phosphorylation during
mitogenic stimulation of G(1)-arrested human breast cancer cells.
Oncogene. 12:2315–2324. 1996.PubMed/NCBI
|
|
24
|
Fu XD, Cui YH, Lin GP and Wang TH:
Non-genomic effects of 17beta-estradiol in activation of the
ERK1/ERK2 pathway induces cell proliferation through upregulation
of cyclin D1 expression in bovine artery endothelial cells. Gynecol
Endocrinol. 23:131–137. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pawar P, Ma L, Byon CH, Liu H, Ahn EY,
Jhala N, Arnoletti JP, McDonald JM and Chen Y: Molecular mechanisms
of tamoxifen therapy for cholangiocarcinoma: Role of calmodulin.
Clin Cancer Res. 15:1288–1296. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Carthy JM, Sundqvist A, Heldin A, van Dam
H, Kletsas D, Heldin CH and Moustakas A: Tamoxifen inhibits
TGF-β-mediated activation of myofibroblasts by blocking non-smad
signaling through ERK1/2. J Cell Physiol. 230:3084–3092. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Warburg O: On the origin of cancer cells.
Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shay JW and Werbin H: Are mitochondrial
DNA mutations involved in the carcinogenic process? Mutat Res.
186:149–160. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Harris MH and Thompson CB: The role of the
Bcl-2 family in the regulation of outer mitochondrial membrane
permeability. Cell Death Differ. 7:1182–1191. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Modica-Napolitano JS and Singh KK:
Mitochondrial dysfunction in cancer. Mitochondrion. 4:755–762.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Boonstra J and Post JA: Molecular events
associated with reactive oxygen species and cell cycle progression
in mammalian cells. Gene. 337:1–13. 2004. View Article : Google Scholar : PubMed/NCBI
|
